ASCO 2020：11项中国分析入选口头报告，17项Poster报告

受全球另行冠疫情不良影响，原订于5翌年29日~6翌年2日在波士顿举行的美国临床学会（ASCO）学术会议今年将首次以线上形式举办，这是目前最大规模的线上盛事。如今，内阁会议的摘录题目公告，共约103个sessions，之中华人民共约和国共约有11项研究者入选为口头报告，17项入选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

苯甲酸替尼或佩佩替尼加卡培他滨使用HER2+冠心病肿瘤症（PHOEBE）：一项III期随机实验。

首站：冠心病肿瘤症

原作者：之中华人民共约和国医学科学院病房徐兵河大学教授、马飞大学教授，复旦大学附属机构病房胡夕春大学教授等

摘录号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三复数肿瘤症标准抗生素后卡培他滨保持稳定人声抗生素的III期实验（SYSUCC-001）。

首站：肿瘤症—区域内/区域/辅助抗生素

原作者：之板桥大学防治之中心地带王为树森大学教授等

摘录号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用冠心病脑的表型特征来分析肾脏之中气化DNA检测的概率: 另行工具箱对抗据闻对手

首站：另行工具箱解决据闻解决办法

原作者：李美芹 李德兰等

摘录号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为之中后期脾细胞内肿瘤的预备队抗生素：一项停止使用标识、随机、多之中心地带II/III期实验。

首站：消化道肿瘤—小肠十二指肠、坏死和脾胆

原作者：湖南大学华西病房毕锋大学教授、之中华人民共约和国人民解放军上海浦东病房秦叔逵大学教授等

摘录号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之中华人民共约和国之中后期脾肿瘤高血压阿帕替尼一线抗生素：一项随机、安慰剂对照、安慰剂III期研究者

首站：消化道肿瘤—小肠十二指肠、坏死和脾胆

原作者：之中华人民共约和国人民解放军上海浦东病房秦叔逵大学教授、湖南大学华西病房李秋大学教授等

摘录号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

之中后期入院连续性卵巢肿瘤二次细胞内减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

讲座：护理人员脾肿瘤

原作者：复旦大学附属机构之板桥病房臧荣余大学教授等

摘录：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治连续性阴道切除术后辅助抗生素之中的序贯放抗生素对比单独放疗或联动放抗生素（STARS研究者）：一项随机、对照、停止使用标识的III期实验。

内阁会议：护理人员脾肿瘤

原作者：之板桥大学防治之中心地带新华大学教授、刘继红大学教授等

摘录号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比抗生素使用可切除的EGFR突变的N1-N2期NSCLC-随机III期临床实验的最终总体生存研究者。

讲座：心肌梗塞—非小细胞内区域内-区域/小细胞内/其他颈部

原作者：广东省人民病房吴一龙大学教授等

摘录号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡转移非小细胞内心肌梗塞高血压预备队酪氨酸丝氨酸类固醇为首或不为首务实前线区域内放疗：III期停止使用标识临床随机实验（SINDAS）的之中期结果（NCT02893332）。

讲座：心肌梗塞-非小细胞内转移

原作者：乐山市人民病房曾铭大学教授等

摘录：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序连续性被害-1（PD-1）的人源化IgG4单克隆抗体为首阿昔替尼使用冠心病皮肤黑色素糙高血压的Ib期研究者的总生存期和海洋生物；也研究者。

讲座：黑色素糙/皮肤肿瘤

原作者：北京大学病房郭军、盛锡楠大学教授等

摘录：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的兼容连续性和结果：区别于CAR-T细胞内首次化学物质实验抗生素入院/难治连续性T细胞内急连续性白血球内肿瘤症（r/r T-ALL）的兼容连续性和。内阁会议：开发之中的抗生素新科技-免疫抗生素。原作者：王为岂料等摘录：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在之中后期十二指肠上皮细胞细胞内肿瘤高血压之中的应用：一项随机的停止使用标识II期实验（ORIENT-2）。内阁会议：消化道肿瘤-小肠十二指肠肿瘤、坏死肿瘤和脾胆道肿瘤原作者：徐建明大学教授等摘录：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D基因表达CAR-T细胞内对髓母细胞内糙的根除连续性抗生素内阁会议：之中枢神经系统原作者：代红久、孙斌、杨东、徐晖、李晶晶、魏佳、陈旭东摘录：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在之中后期错配修复缺失高血压之中的应用内阁会议：开发之中的抗生素学-免疫抗生素原作者：沈琳大学教授等摘录：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART抗生素入院/难治连续性ACUTE白血球内肿瘤症/淋巴糙的尚属化学物质临床实验内阁会议: 开发连续性抗生素学-免疫抗生素原作者简介：张明志，陈东等摘录：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度酮（T）为首应使用之中后期实体糙高血压的Ib期研究者内阁会议：发展连续性抗生素学--小分子靶向药品和海洋生物学原作者：龚继芳，沈琳大学教授等摘录：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin为首紫杉醇和nedaplatin抗生素入院连续性或冠心病十二指肠上皮细胞细胞内肿瘤（ESCC）高血压的II期研究者。内阁会议：消化道肿瘤-小肠十二指肠、坏死和脾胆道肿瘤的研究者原作者：王为志极强，李玉红，王为德申，王为凤华，任超，谭琼 王为志极强、李玉红、王为德深、王为凤华、任超、谭琼摘录：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：消化道肿瘤-小肠十二指肠肿瘤、坏死肿瘤和脾胆管肿瘤的一线抗生素原作者：宋艳等摘录：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体外缘RNA特征向量使用初始活检时检测高等级肿瘤的唾液外体外缘RNA特征向量：一项多之中心地带的回顾连续性研究者内阁会议：移行生殖系统脾肿瘤---肿瘤、子宫颈肿瘤和肿瘤原作者简介：Liaoyuan Li等摘录：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 区域内之中后期宫颈肿瘤所发抗生素后的辅助抗生素内阁会议: 护理人员脾肿瘤原作者简介： 李珉珉等摘录：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼抗生素甲状腺髓连续性肿瘤的相关连续性：基于ALTER01031实验的研究者。会话：多毛原作者：济南市病房实是大学教授摘录：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和岁数对安洛替尼抗生素后高血压结局的不良影响: ALTER01031的亚组研究者内阁会议：多毛原作者：济南市病房实是大学教授摘录：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA研究者分析I-IIIA期非小细胞内心肌梗塞（NSCLC）高血压术后入院: GASTO1035和GASTO1018的结果内阁会议：心肌梗塞-非小细胞内区域内-区域连续性/小细胞内/小细胞内/其他胸科脾肿瘤原作者：Si-Yu Wang等摘录：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞内心肌梗塞（NSCLC）之中EGFR酪氨酸丝氨酸类固醇的另行型耐药机制内阁会议:心肌梗塞-非小细胞内冠心病心肌梗塞原作者简介：陈昕，金玲玲，满宇，欧秋香，双带，薛武，杨少，范敏 陈昕、金玲玲、满宇、欧秋香、双带、薛武、杨绍、范敏摘录：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验之中之中后期黑色素糙总生存的替代终点内阁会议：黑色素糙/皮肤肿瘤原作者：聂润聪，袁书极强，李元芳，陈英波，周志伟 聂润聪、袁书极强、李元芳、陈英波、周志伟摘录：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼抗生素入院或冠心病原发连续性恶连续性穿孔高血压的II期研究者内阁会议： 肉糙原作者：唐丽娜，牛晓辉，王为震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王为振、蔡启庆、涂崇奇、范正福、杨瑶摘录：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在之中后期肉糙高血压多线抗生素之中的兼容连续性和。内阁会议：肉糙原作者：姚伟涛，王为家极强，张鹏，王为欣，杜另行辉，田志浩，牛晓颖 姚伟涛、王为家极强、张鹏、王为鑫、杜鑫辉、田志超、牛晓英摘录：11526广告：414